Seattle Children's Research Institute

Seattle Children’s Hospital Board announces the creation of Seattle Children’s Research Institute.

Donor-funded Science Adventure Lab debuts as the Pacific Northwest’s first mobile lab for student education.

Seattle Children’s leads a landmark Phase 3 trial that targets the underlying cause of cystic fibrosis.

The Towne family’s generosity leads to the naming of the Ben Towne Center for Childhood Cancer and Blood Disorders Research.

Researchers lead the first FDA approved fecal transplant study for children with Crohn’s disease.

Seattle Children’s becomes a global leader in CAR T-cell therapy with a landmark trial resulting in a 93% remission rate for relapsed leukemia.

Center for Infectious Disease Research joins the research institute to form the largest pediatric infectious disease research center in the U.S.

Building Cure opens, with dedicated space to produce therapeutic products. Today the building is named after B. Wayne Hughes in honor of his family’s philanthropy.

Seattle Children’s Therapeutics launches to accelerate research and development of cutting-edge therapies.

A $55 million investment enabled by philanthropy launches Invent at Seattle Children’s Postdoctoral Scholars Program to support early career scientists.

Seattle Children’s establishes a new model for pediatric research by spinning out the institution-owned biotech company to scale lifesaving therapies globally.

Seattle Children’s launches the first CAR T-cell clinical trial in the U.S. for children with systemic lupus erythematosus.

Researchers publish a revolutionary genetic approach showing promise in treating the deadly pediatric seizures caused by Dravet syndrome.